Ralph Weichselbaum to Combined Modality Therapy
This is a "connection" page, showing publications Ralph Weichselbaum has written about Combined Modality Therapy.
Connection Strength
4.388
-
Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease. Clin Cancer Res. 2025 Jul 01; 31(13):2556-2564.
Score: 0.171
-
Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024 08; 25(8):e352-e362.
Score: 0.161
-
Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal. Eur J Cancer. 2024 04; 201:113972.
Score: 0.156
-
Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
Score: 0.133
-
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
Score: 0.132
-
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
Score: 0.122
-
Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
Score: 0.114
-
Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
Score: 0.114
-
Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 09; 14(9):1510-1512.
Score: 0.113
-
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017 Jun; 14(6):365-379.
Score: 0.095
-
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016 Jul 12; 7(28):43039-43051.
Score: 0.092
-
Comparison of 3D confromal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. PLoS One. 2014; 9(4):e94456.
Score: 0.079
-
Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol Ther. 2012 May; 20(5):1046-55.
Score: 0.068
-
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011 Nov; 18(11):1098-102.
Score: 0.064
-
The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010 Aug; 7(8):437-47.
Score: 0.061
-
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res. 2010 Aug 01; 70(15):6277-82.
Score: 0.061
-
Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):38-46.
Score: 0.054
-
More on cetuximab in head and neck cancer. N Engl J Med. 2007 Nov 22; 357(21):2201-2; author reply 2202-3.
Score: 0.051
-
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res. 2007 Oct 15; 13(20):6217-23.
Score: 0.050
-
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.045
-
Chemo-inducible gene therapy. Anticancer Drugs. 2005 Nov; 16(10):1053-8.
Score: 0.044
-
How does antiangiogenic therapy affect brain tumor response to radiation? Nat Clin Pract Oncol. 2005 May; 2(5):232-3.
Score: 0.042
-
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol. 2025 Mar; 26(3):e152-e170.
Score: 0.042
-
Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol. 2005 Feb; 2(2):60-1.
Score: 0.042
-
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. Oncoimmunology. 2025 Dec; 14(1):2432726.
Score: 0.041
-
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res. 2004 Sep 15; 64(18):6381-4.
Score: 0.041
-
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004 Sep 01; 10(17):5747-53.
Score: 0.040
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.040
-
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
Score: 0.037
-
Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res. 2003 Jan 15; 63(2):308-11.
Score: 0.036
-
Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. Am Surg. 2003 Jan; 69(1):24-7.
Score: 0.036
-
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
Score: 0.036
-
Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov; 3(11):665-71.
Score: 0.036
-
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 2002 Jan; 9(1):75-80.
Score: 0.034
-
Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. Int J Oncol. 2001 Oct; 19(4):833-5.
Score: 0.033
-
Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol. 2001 Oct; 11(4):338-45.
Score: 0.033
-
Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. Int J Radiat Oncol Biol Phys. 2021 12 01; 111(5):1165-1175.
Score: 0.033
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.032
-
Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001; 40(6):735-8.
Score: 0.031
-
Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000 Sep-Oct; 6(5):287-93.
Score: 0.031
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.030
-
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999 Jun; 5(6):1517-22.
Score: 0.028
-
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
Score: 0.028
-
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019 Jan 28; 14(1):18.
Score: 0.027
-
Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig. 1999; 7(5):261-9.
Score: 0.027
-
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998 Dec 15; 58(24):5686-9.
Score: 0.027
-
Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998 Nov-Dec; 5(6):344-9.
Score: 0.027
-
Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin-chimeric protein. Cancer Res. 1998 Aug 01; 58(15):3215-20.
Score: 0.027
-
Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998 Jul 16; 394(6690):287-91.
Score: 0.026
-
Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun. 2018 06 15; 9(1):2351.
Score: 0.026
-
Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018 08; 2(8):600-610.
Score: 0.026
-
Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998 Mar; 5(3):293-300.
Score: 0.026
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.026
-
Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998 Feb; 5(2):160-5.
Score: 0.026
-
Role of gene therapy in radiation oncology. Cancer Treat Res. 1998; 93:153-67.
Score: 0.025
-
Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
Score: 0.025
-
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 07; 59(7):1666-1671.
Score: 0.025
-
Nasopharyngeal carcinoma. Lancet. 1997 Oct 11; 350(9084):1087-91.
Score: 0.025
-
Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 1997 Oct 01; 57(19):4205-9.
Score: 0.025
-
Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. 1997 Oct 01; 57(19):4340-7.
Score: 0.025
-
Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers. Head Neck. 2017 12; 39(12):2537-2548.
Score: 0.025
-
Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.
Score: 0.024
-
Increased injection number enhances adenoviral genetic radiotherapy. Radiat Oncol Investig. 1997; 5(5):220-6.
Score: 0.024
-
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. J Am Chem Soc. 2016 12 28; 138(51):16686-16695.
Score: 0.024
-
Breast preservation in stage I and II carcinoma of the breast. The University of Chicago experience. Cancer. 1996 Oct 15; 78(8):1722-30.
Score: 0.023
-
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene. 2017 02 02; 36(5):585-592.
Score: 0.023
-
Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 1995 Dec 01; 55(23):5561-5.
Score: 0.022
-
Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1995 Sep 30; 33(2):261-70.
Score: 0.022
-
Radiation oncology and the new biology. Cancer J Sci Am. 1995 Sep-Oct; 1(3):174-9.
Score: 0.022
-
Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am. 1995 Sep-Oct; 1(3):204-9.
Score: 0.022
-
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):47-52.
Score: 0.021
-
Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res. 1995 Mar 01; 55(5):991-4.
Score: 0.021
-
Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest. 1995; 13(5):453-9.
Score: 0.021
-
Surgical management of the head and neck cancer patient following concomitant multimodality therapy. Laryngoscope. 1995 Jan; 105(1):97-101.
Score: 0.021
-
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Jul; 22(7):2209-17.
Score: 0.021
-
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
Score: 0.020
-
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):151-60.
Score: 0.020
-
Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994 Aug 15; 54(16):4266-9.
Score: 0.020
-
Effect of postradiotherapy neck dissection on nonregional disease sites. JAMA Otolaryngol Head Neck Surg. 2014 Jan; 140(1):12-21.
Score: 0.019
-
Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
Score: 0.019
-
Measurable impact: multimodality therapy of head and neck cancer. Int J Radiat Oncol Biol Phys. 1993 Sep 30; 27(2):481-2.
Score: 0.019
-
Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013 Jul; 8(7):915-22.
Score: 0.019
-
Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012 May; 27(5):1625-9.
Score: 0.017
-
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992; 49(6):454-60.
Score: 0.017
-
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
Score: 0.017
-
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.017
-
Chemotherapeutic and biologic radiation enhancement. Curr Opin Oncol. 1991 Dec; 3(6):1087-95.
Score: 0.017
-
Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
Score: 0.017
-
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.017
-
Recent advances in radiation therapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):635-55.
Score: 0.016
-
Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):753-67.
Score: 0.016
-
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol. 1991 Aug; 9(8):1376-84.
Score: 0.016
-
Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):413-7.
Score: 0.016
-
Palliative radiotherapy. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1169-81.
Score: 0.016
-
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13.
Score: 0.015
-
Radiation or surgery for chemodectoma of the temporal bone: a review of local control and complications. Head Neck. 1990 Jul-Aug; 12(4):303-7.
Score: 0.015
-
Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. J Surg Oncol. 1990 Jul; 44(3):157-65.
Score: 0.015
-
Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990 May; 8(5):911-34.
Score: 0.015
-
Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
Score: 0.015
-
Breast conserving surgery and definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1211-6.
Score: 0.015
-
Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):761-6.
Score: 0.014
-
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
Score: 0.014
-
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.014
-
Characterization of response to radiation mediated gene therapy by means of multimodality imaging. Magn Reson Med. 2009 Aug; 62(2):348-56.
Score: 0.014
-
Management of stage I and II Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):253-63.
Score: 0.014
-
Substaging of stage III Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):277-86.
Score: 0.014
-
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
Score: 0.014
-
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009 Jul 16; 114(3):589-95.
Score: 0.014
-
Treatment selection in T1 and T2 vocal cord carcinoma. Oncology (Williston Park). 1988 Oct; 2(10):41-50.
Score: 0.013
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.013
-
Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis. 2007; 24(7):521-31.
Score: 0.012
-
Multidisciplinary treatment of advanced squamous carcinoma of the head and neck. Semin Oncol. 1985 Dec; 12(4 Suppl 6):71-8.
Score: 0.011
-
Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep; 56(3):317-21.
Score: 0.011
-
Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy. Cancer. 1985 May 01; 55(9 Suppl):2149-55.
Score: 0.011
-
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.010
-
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15; 22(4):592-601.
Score: 0.010
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.010
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.009
-
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
Score: 0.009
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.009
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.009
-
Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002 Sep; 8(9):551-63.
Score: 0.009
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.009
-
Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther. 2001 Jun 10; 12(9):1109-31.
Score: 0.008
-
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
Score: 0.008
-
Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol. 2001 Mar; 12(3):343-7.
Score: 0.008
-
The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
Score: 0.008
-
Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
Score: 0.007
-
Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999 Jul-Aug; 5(4):230-6.
Score: 0.007
-
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
Score: 0.007
-
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
Score: 0.007
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
Score: 0.006
-
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
Score: 0.006
-
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
Score: 0.006
-
Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1127-35.
Score: 0.005
-
Timing and sequencing of chemoradiotherapy. Cancer Treat Res. 1995; 74:173-98.
Score: 0.005
-
Combined modality therapy of head and neck cancer. Semin Oncol. 1994 Jun; 21(3):349-58.
Score: 0.005
-
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
Score: 0.005
-
Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):743-6.
Score: 0.005
-
Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol. 1993 Apr; 149(4):753-7.
Score: 0.005
-
Head and neck cancer. N Engl J Med. 1993 Jan 21; 328(3):184-94.
Score: 0.005
-
Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1992 Aug; 19(4 Suppl 11):47-56.
Score: 0.004
-
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
Score: 0.004
-
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
Score: 0.004
-
Preoperative radiotherapy followed by radical vulvectomy with inguinal lymphadenectomy for advanced vulvar carcinomas. Gynecol Oncol. 1990 Feb; 36(2):181-4.
Score: 0.004
-
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
Score: 0.004
-
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol. 1989 Jul; 7(7):838-45.
Score: 0.004
-
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
Score: 0.003
-
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
Score: 0.003
-
Prophylactic cranial irradiation in adenocarcinoma of the lung. A possible role. Cancer. 1987 Jun 15; 59(12):2016-9.
Score: 0.003
-
An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan; 5(1):10-20.
Score: 0.003
-
Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1985 Nov; 11(11):1887-93.
Score: 0.003
-
Treatment of perineural metastasis from squamous carcinoma of the skin with aggressive combination chemotherapy and irradiation. J Surg Oncol. 1985 Jul; 29(3):181-3.
Score: 0.003
-
The role of post-operative radiation therapy in the treatment of malignant tumors of the parotid gland. J Surg Oncol. 1984 Nov; 27(3):163-7.
Score: 0.003
-
Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate. Arch Otolaryngol. 1984 Apr; 110(4):241-5.
Score: 0.002
-
Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck. Laryngoscope. 1984 Apr; 94(4):451-54.
Score: 0.002